To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Is plasma amyloid-beta a … - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Is plasma amyloid-beta a reliable biomarker for Alzheimer's disease?

Review article
Authors Henrik Zetterberg
Published in Recent patents on CNS drug discovery
Volume 3
Issue 2
Pages 109-11
ISSN 1574-8898
Publication year 2008
Published at Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Pages 109-11
Language en
Links www.ncbi.nlm.nih.gov/entrez/query.f...
Keywords Alzheimer Disease, blood, cerebrospinal fluid, economics, Amyloid beta-Protein, blood, cerebrospinal fluid, Biological Markers, Cognition Disorders, blood, cerebrospinal fluid, etiology, Humans, Peptide Fragments, blood, cerebrospinal fluid
Subject categories Medical and Health Sciences

Abstract

Over the past decade, a tremendous amount of consistent data have accumulated showing reduced levels of the 42 amino acid isoform of amyloid-beta (Abeta(42)) in cerebrospinal fluid (CSF) from patients with mature as well as incipient Alzheimer's disease (AD). However, as CSF analyses necessitate a spinal tap, which some consider hard to implement in the clinical routine and in clinical trials, there is a strong interest in the possible association of Abeta levels in plasma with AD. This review provides an update on the current status of research on plasma Abeta as a biomarker for AD in the context of recent patents in the field.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?

Denna text är utskriven från följande webbsida:
http://www.gu.se/english/research/publication/?publicationId=78818
Utskriftsdatum: 2020-04-02